Orphanet: Wyszukaj lek sierocy
Wyszukaj lek sierocy
123 Wyniki
- (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol
- 1,2-bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine
- 1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea
- 1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
- 1-[2-(Benzo[1,2,5]thiadiazol-5-ylamino)-6-(2,6-dichloro-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3- tert-butyl-urea
- 2,6-Dichloro-N-(3-isobutyl-1,5-dimethyl-1H-pyrazol-4-yl)-4-(2-(piperazin-1-yl)pyridin-4-yl)benzenesulfonamide
- 2-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-N-((5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)acetamide, tetrahydrochloride
- 2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2,-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate
- 2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}- 1H-pyrazol-3-yl)amino]- quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate
- 2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one
- 225Ac-lintuzumab
- 26 base single stranded phosphodiester DNA oligonucleotide
- 5'-O-(trans-9"-octadecenoyl)-1-ß-D-arabinofuranosyl cytosine
- 6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate
- A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha variant 1 genetically linked to a modified and inactive Fc domain of human IgG
- AB8939
- Allogeneic T cells encoding an exogenous TK gene
- Allogeneic bone marrow stem cells treated ex vivo with 16,16-dimethyl prostaglandin E2
- Allogeneic ex vivo expanded umbilical cord blood cells
- Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells
- Allogeneic human dendritic cells derived from a CD34+ progenitor cell line
- Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus
- Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2
- Allogeneic, umbilical cord blood-derived, ex vivo-expanded, haematopoietic CD133+ cells / allogeneic, umbilical cord blood-derived, non-expanded, haematopoietic CD133- cells
- Alvocidib
- Amonafide L-malate
- Antisense oligonucleotide 5'-d[P-Thio} (CCCTG CTCCC CCCTG GCTCC)-3'
- Arsenic trioxide
- Aspacytarabine
- Autologous T cells transduced with a lentiviral vector expressing a chimeric antigen receptor against CLL-1
- Autologous chimeric antigen receptor (CAR) T-cell therapy engineered to express an antibody-derived single-chain variable fragment that recognizes C-type lectin-like molecule-1 (CLL-1)
- Azacitidine
- Bisantrene hydrochloride
- Clofarabine
- Combretastatin A1 diphosphate
- Crenolanib besylate
- Daunorubicin (liposomal)
- Decitabine
- Devimistat
- Donor lymphocyte preparation depleted of functional alloreactive T-cells
- Enasidenib
- Entospletinib
- Eryaspase
- Fully human IgG1 antibody specific for CD33
- Gemtuzumab Ozogamicin
- Gilteritinib
- Glasdegib
- Guadecitabine
- Histamine dihydrochloride
- Homoharringtonine
- Human monoclonal antibody against inhibitory killer cell lg-like receptors (1-7 F9)
- Idasanutlin
- Inecalcitol
- Isocitrate dehydrogenase 2-mutant inhibitor
- Ivosidenib
- L-Asparaginase
- Laromustine
- Lestaurtinib
- Lintuzumab
- Liposomal combination of cytarabine and daunorubicin
- Liposomal daunorubicin
- Luveltamab tazevibulin
- Menin inhibitor
- Midostaurin
- Mitoxantrone
- N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide
- N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy)imidazo[2,1- b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt
- N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride
- N-hydroxy-4-((4-((((1R,2S)-2-phenylcyclopropyl) amino)methyl)-1H-pyrazol-1-yl)methyl)benzamide hydrogen bromide
- NEDD8-activating enzyme (NAE) inhibitor
- Olutasidenib
- Onvansertib
- P-ethoxy growth factor receptor-bound protein 2 (Grb2) antisense oligonucleotide
- Plerixafor
- Pracinostat
- Radgocitabine
- Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3
- Ribonucleotide reductase R2 specific phosphorothioate oligonucleotide
- SEL24/MEN1703
- Sapacitabine
- Selinexor
- T cell therapeutic product obtained from transduction of chimeric T cell receptor synthetic T cell receptor and antigen receptor (STAR)
- Tamibarotene
- Tipifarnib
- Tosedostat
- Trans N-ethyl-2-((4-(7-((4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide sesquifumarate
- Troxacitabine
- Ulocuplumab
- Vadastuximab talirine
- Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3)
- Venetoclax
- Volasertib
- Vosaroxin
- Wilms' tumour 1 (WT1) vaccine
- Zosuquidar trihydrochloride
- cedazuridine and decitabine
- cenisertib
- cusatuzumab
- haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate
- humanised monoclonal antibody of the IgG4 kappa isotype targeting CD47
- lysine-specific histone demethylase (LSD1, also known as KDM1A) inhibitor
- tagraxofusp
